| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE | James Basta, attorney-in-fact | 07 Jan 2026 | 0001914448 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NTLA | Common Stock | Sale | $87,633 | -9,515 | -9.8% | $9.21 | 87,118 | 05 Jan 2026 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person. |
| F2 | Includes 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2025. |